Market cap of Supernus Pharmaceuticals, Inc.
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company??s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|ACTA Actua Corporation||NASDAQ > Technology > EDP Services||73.30%|
|BFS Saul Centers, Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||73.33%|
|LPSN LivePerson, Inc.||NASDAQ > Technology > Computer Software: Prepackaged Software||73.35%|
|BCEI Bonanza Creek Energy, Inc.||NYSE > Energy > Oil & Gas Production||73.36%|
|KRG Kite Realty Group Trust||NYSE > Consumer Services > Real Estate Investment Trusts||73.41%|
|HTLD Heartland Express, Inc.||NASDAQ > Transportation > Trucking Freight/Courier Services||73.46%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||73.51%|
|WF Woori Bank||NYSE > Finance > Commercial Banks||98,929.06%|
|SHG Shinhan Financial Group Co Ltd||NYSE > Finance > Major Banks||99,422.33%|
|CIB BanColombia S.A.||NYSE > Finance > Commercial Banks||271,056.66%|
|AVAL Grupo Aval Acciones y Valores S.A.||NYSE > Finance > Commercial Banks||289,792.65%|
|TLK PT Telekomunikasi Indonesia, Tbk||NYSE > Public Utilities > Telecommunications Equipment||731,941.22%|
|PRKR ParkerVision, Inc.||NASDAQ > Technology > Radio And Television Broadcasting And Communications Equipment||1,990,485.56%|